{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T19:09:57Z","timestamp":1773428997541,"version":"3.50.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The aim of the study was to describe the incidence and type of bacterial infections associated with the use of ciprofloxacin prophylaxis as single agent in pediatric patients with acute myeloid leukemia (AML).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Procedure:<\/jats:title>\n            <jats:p>This was a retrospective review of all patients with AML, who were treated according to the AML02 protocol between 2011 and 2015. The medical records were reviewed for any positive cultures from the initiation of the protocol until death or protocol discontinuation. Patient demographics, type of infections, type of isolated bacteria, and intensive care unit admissions were recorded.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 50 patients were evaluated, who were of a mean age of 8 years\u00b15.1 (SD). We identified 77 episodes of bacterial infections in 42 (84%) patients. Among those bacterial infections, 73 episodes were with bacteremia and included 45 (62%) gram-positive bacterial infections, 24 (33%) gram-negative bacterial infections, and 4 (6%) mixed gram-negative and gram-positive bacterial infections. Coagulase-negative <jats:italic toggle=\"yes\">Staphylococcus<\/jats:italic> and <jats:italic toggle=\"yes\">Viridans streptococci<\/jats:italic> were the most commonly isolated bacteria in 33% and 30% of the episodes, respectively. Seventeen (45%) patients with bacteremia required intensive care unit admission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A high rate of bacterial infection was detected in patients who received the AML02 protocol, mainly gram-positive bacterial infections. The prophylactic regimen should be reconsidered for its efficacy, and other antibacterial prophylaxis may be used.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000000792","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T15:29:39Z","timestamp":1487950179000},"page":"e131-e135","source":"Crossref","is-referenced-by-count":12,"title":["Bacterial Infections in Children With Acute Myeloid Leukemia Receiving Ciprofloxacin Prophylaxis"],"prefix":"10.1097","volume":"39","author":[{"given":"Suha","family":"Al Omar","sequence":"first","affiliation":[{"name":"Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Anabtawi","sequence":"additional","affiliation":[{"name":"Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiam","family":"Al Qasem","sequence":"additional","affiliation":[{"name":"Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rawad","family":"Rihani","sequence":"additional","affiliation":[{"name":"Pediatric Oncology, Pediatric Bone Marrow and Stem Cell Transplantation, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/jcm4010127","article-title":"Pediatric AML: from biology to clinical management","volume":"4","author":"De Rooij","year":"2015","journal-title":"J Clin Med"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2010.30.6829","article-title":"Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate","volume":"29","author":"Abrahamsson","year":"2011","journal-title":"J Clin Oncol"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1200\/JCO.2004.01.191","article-title":"Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98","volume":"22","author":"Creutzig","year":"2004","journal-title":"J Clin Oncol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1365-2141.1999.01550.x","article-title":"Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10)","volume":"106","author":"Riley","year":"1999","journal-title":"Br J Haematol"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/blood-2007-05-091942","article-title":"Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia","volume":"110","author":"Sung","year":"2007","journal-title":"Blood"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1200\/JCO.2000.18.9.1845","article-title":"Alpha hemolytic Streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children\u2019s cancer group study CCG-2891","volume":"18","author":"Gamis","year":"2000","journal-title":"J Clin Oncol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/cncr.23563","article-title":"Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia","volume":"113","author":"Kurt","year":"2008","journal-title":"Cancer"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/pbc.24448","article-title":"High frequency of streptococcal bacteremia during childhood AML therapy irrespective of dose of cytarabine","volume":"60","author":"Johanssen","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.28688","article-title":"Feasibility, efficacy and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia","volume":"120","author":"Inaba","year":"2014","journal-title":"Cancer"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/cncr.28524","article-title":"Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole or micafungin prophylaxis","volume":"120","author":"Yeh","year":"2014","journal-title":"Cancer"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/pbc.25463","article-title":"Preventive antibiotics in pediatric patients with acute myeloid leukemia (AML)","volume":"62","author":"Nolt","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukemia: results of the AML02 multicenter trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/leu.2009.30","article-title":"Combination of cladrabine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial","volume":"23","author":"Rubnitz","year":"2009","journal-title":"Leukemia"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijid.2007.04.020","article-title":"Risk factors for rectal colonization with vancomycin-resistant enterococci in Shiraz, Iran","volume":"12","author":"Askarian","year":"2008","journal-title":"Int J Infect Dis"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/jac\/dkr204","article-title":"Risk factors for prolonged carriage of vancomycin-resistant enterococcus faecium among patients in intensive care units: a case-control study","volume":"66","author":"Yoon","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1200\/JCO.2006.08.7395","article-title":"Rational selection of patients for antimicrobial prophylaxis after chemotherapy","volume":"25","author":"Cullen","year":"2007","journal-title":"J Clin Oncol"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/sj.bjc.6605270","article-title":"Prevention of febrile neutropenia: use of prophylactic antibiotics","volume":"101","author":"Cullen","year":"2009","journal-title":"Br J Cancer"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"p581","DOI":"10.1097\/INF.0b013e318286f91f","article-title":"Ciprofloxacin prophylaxis in children with acute leukemia in an era of increasing antibiotic resistance","volume":"32","author":"Elio","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1097\/INF.0b013e3182793610","article-title":"Ciprofloxacin reduces occurrence of fever in children with acute leukemia who develop neutropenia during chemotherapy","volume":"32","author":"Laoprasopwattana","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R20-20230918","first-page":"CD004386","article-title":"Antiboitic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"1","author":"Gafter-Gvili","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R21-20230918","first-page":"61","article-title":"Development of stable oral suspension of ciprofloxacin","volume":"3","author":"Nahata","year":"2000","journal-title":"J Appl Ther Res"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious disease society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin infect dis"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1177\/1078155215591386","article-title":"Vancomycin pharmacokinetics and predicted dosage requirements in cancer patients","volume":"22","author":"Addel Hadi","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1086\/340352","article-title":"Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis","volume":"34","author":"Razonable","year":"2002","journal-title":"Clin Infect Dis J"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1086\/340402","article-title":"Infections caused by viridans streptococci in patients with neutropenia","volume":"34","author":"Tunkel","year":"2002","journal-title":"Clin Infect Dis J"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/clinids\/18.1.25","article-title":"Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors","volume":"18","author":"Bochud","year":"1994","journal-title":"Clin Infect Dis J"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/pbc.20065","article-title":"A pilot study of prophylactic ciprofloxacin during delayed intensification in children with acute lymphoblastic leukemia","volume":"43","author":"Yousef","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/clinids\/14.6.1201","article-title":"Septicemia and shock syndrome due to viridans streptococci: a case control-study of predisposing factors","volume":"14","author":"Elting","year":"1992","journal-title":"Clin Infect Dis"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/BF01642101","article-title":"Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases","volume":"18","author":"Kern","year":"1990","journal-title":"Infection"},{"key":"R30-20230918","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0924-8579(99)00172-7","article-title":"Viridans-group streptococcal infections in immunocompromised hosts","volume":"14","author":"Shenep","year":"2000","journal-title":"Int J Antimicrob Agents"},{"key":"R31-20230918","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1086\/317460","article-title":"Serious complications of bacteremia caused by viridans streptococci in neutropenic patients with cancer","volume":"31","author":"Marron","year":"2000","journal-title":"Clin Infect Dis J"},{"key":"R32-20230918","first-page":"453","article-title":"Septicemia in pediatric oncology patients: the significance of viridans streptococcal infections","volume":"8","author":"Weisman","year":"1990","journal-title":"Clin Infect Dis J"},{"key":"R33-20230918","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1186\/1471-2334-13-563","article-title":"Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis","volume":"13","author":"De Rosa","year":"2013","journal-title":"BMC Infect Dis"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201704000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T05:02:40Z","timestamp":1695013360000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201704000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000000792","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}